Neonatal metabolic disorders screening

Introduction: Neonatal metabolic disorders screening is a programmatic approach to test newborns for a set of inherited metabolic disorders (inborn errors of metabolism, IEMs) shortly after birth. Typically done via dried blood spot testing (heel-prick) with a tiered algorithm: initial screen, followed by confirmatory tests as needed. key goals: Early detection of treatable conditions to prevent irreversible damage (e.g., developmental delay, organ failure, or death). Enable timely initiation of interventions (dietary modifications, vitamins/cofactors, medications) to improve outcomes. Reduce long-term healthcare burden through prevention of severe complications. common screens and panel evolution: Classic panels screen for core IEMs such as phenylketonuria (PKU), medium-chain acyl-CoA dehydrogenase deficiency (MCADD), maple syrup urine disease (MSUD), galactosemia, congenital hypothyroidism, severe combined immunodeficiency (SCID) in broader programs, etc. Modern tandem mass spectrometry (MS/MS) expands panels to dozens of metabolites, enabling detection of multiple aminoacidopathies, organic acidurias, fatty acid oxidation disorders, and more. Some programs include second-tier tests or molecular/genome-based confirmatory steps to reduce false positives and improve diagnostic precision. Benefits: Timely treatment reduces morbidity and mortality. Decreased incidence of disability from certain metabolic crises. Improved family counseling and planning due to earlier diagnosis. challenges and considerations; False positives and false negatives can cause parental anxiety or missed diagnoses. Turnaround time for results and confirmatory testing is critical. Equity and access: ensuring all newborns have access to universal screening and follow-up care. Cost-effectiveness and resource allocation, especially in low-resource settings.